Nilotinib Stada (Nilotinib)

• Nilotinib is used in the treatment of chronic myeloid leukemia, a BCR‑ABL driven hematologic malignancy.
• Philadelphia chromosome‑positive chronic myeloid leukemia (CML) in adults: achieves disease control by inhibiting BCR‑ABL tyrosine kinase activity, leading to reduced leukemic cell proliferation.

• Nilotinib selectively binds to the ATP‑binding site of the BCR‑ABL tyrosine kinase, stabilizing the inactive conformation of the enzyme. By preventing phosphorylation of downstream substrates, it blocks signal transduction pathways that drive proliferation and survival of leukemic cells, resulting in cytostatic and cytotoxic effects in Philadelphia‑positive disease. The inhibition is highly specific, sparing most other kinases, which contributes to its therapeutic profile.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: loose stools that may require hydration.
• Rash: skin erythema or pruritus.
• Fatigue: general tiredness or weakness.

Serious or Rare Side Effects

• Cardiovascular events: including arterial occlusive disease or ischemic heart disease.
• Hepatotoxicity: elevated liver enzymes or hepatitis.
• Pancreatitis: inflammation of the pancreas, presenting with abdominal pain.

When prescribing Nilotinib, clinicians should observe several precautionary measures to minimize risks.

• Baseline cardiac assessment: evaluate history of cardiovascular disease before initiating therapy.
• Monitor liver function: perform periodic liver enzyme tests during treatment.
• Assess pancreatic enzymes: check amylase and lipase regularly to detect pancreatitis.
• Avoid concomitant strong CYP3A4 inhibitors: they can increase nilotinib plasma levels.
• Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with specialist.
• Store at ambient temperature: keep below 25 °C in original container, protect from moisture and light.

Nilotinib interacts with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase nilotinib exposure.
• Proton pump inhibitors (e.g., omeprazole) taken concomitantly: can reduce nilotinib absorption.
• Antacids containing aluminum or magnesium: may decrease bioavailability.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower nilotinib concentrations.
• Anticoagulants (e.g., warfarin): nilotinib may affect INR, requiring monitoring.
• Statins metabolized by CYP3A4 (e.g., simvastatin): increased risk of statin‑related toxicity.